{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:05:37Z","timestamp":1791201937689,"version":"4.2.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-026-02748-8","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:09:17Z","timestamp":1783937357000},"page":"1629-1632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The end of the primary\u2013secondary prevention dichotomy in high-risk diabetes? Lessons from VESALIUS-CV"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-1374","authenticated-orcid":false,"given":"Salvatore","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"9374","key":"2748_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"Heart Protection Study Collaborative Group","year":"2003","unstructured":"Heart Protection Study Collaborative Group (2003) MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005\u20132016","journal-title":"Lancet"},{"issue":"9435","key":"2748_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes mellitus in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685\u2013696","journal-title":"Lancet"},{"issue":"9607","key":"2748_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607):117\u2013125","journal-title":"Lancet"},{"issue":"9753","key":"2748_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"issue":"9841","key":"2748_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Collaborators, Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT), Collaborators, Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581\u2013590","journal-title":"Lancet"},{"issue":"32","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38(32):2459\u20132472","journal-title":"Eur Heart J"},{"issue":"25","key":"2748_CR7","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. Circulation 139(25):e1082\u2013e1143","journal-title":"Circulation"},{"issue":"Suppl 1","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S216\u2013S245","journal-title":"Diabetes Care"},{"issue":"1","key":"2748_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"42","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE et al (2025) 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359\u20134378","journal-title":"Eur Heart J"},{"issue":"2","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","volume":"394","author":"EA Bohula","year":"2026","unstructured":"Bohula EA, Marston NA, Bhatia AK et al (2026) Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med 394(2):117\u2013127","journal-title":"N Engl J Med"},{"key":"2748_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.3277","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bohula EA, Bhatia AK et al (2026) Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2026.3277","journal-title":"JAMA"},{"issue":"22","key":"2748_CR13","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316(22):2373\u20132384","journal-title":"JAMA"},{"issue":"25","key":"2748_CR14","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jacc.2011.02.038","volume":"57","author":"HE Bays","year":"2011","unstructured":"Bays HE (2011) Adiposopathy: is sick fat a cardiovascular disease? J Am Coll Cardiol 57(25):2461\u20132473","journal-title":"J Am Coll Cardiol"},{"key":"2748_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/obr.70155","author":"S Corrao","year":"2026","unstructured":"Corrao S, Tuccinardi D, Baratta R et al (2026) Beyond weight loss: obesogenic memory as biological hysteresis in adipose tissue revealed by AI semantic mapping with an exportable core corpus. Obes Rev. https:\/\/doi.org\/10.1111\/obr.70155","journal-title":"Obes Rev"},{"key":"2748_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00592-025-02556-6","volume":"62","author":"S Corrao","year":"2025","unstructured":"Corrao S, Federici M (2025) Unmasking heterogeneity in type 2 diabetes: the clinical relevance of phenotyping in the era of precision medicine. Acta Diabetol 62:1167\u20131172. https:\/\/doi.org\/10.1007\/s00592-025-02556-6","journal-title":"Acta Diabetol"},{"key":"2748_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2026.113243","author":"S Corrao","year":"2026","unstructured":"Corrao S, Scibetta S, Mirarchi L, Amodeo S, Corrao G, Calvo L (2026) Adaptive evidence-based medicine in type 2 diabetes: beyond the average effect toward personalised clinical decision-making for a humanised medicine. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2026.113243","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02748-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:49:09Z","timestamp":1791200949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02748-8","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to affiliation 3 was incorrect in the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}